Publication: Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand
Issued Date
2000-06-19
Resource Type
ISSN
13520504
Other identifier(s)
2-s2.0-0034044367
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Viral Hepatitis. Vol.7, No.SUPPL. 1 (2000), 11-12
Suggested Citation
C. Pramoolsinsap Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand. Journal of Viral Hepatitis. Vol.7, No.SUPPL. 1 (2000), 11-12. doi:10.1046/j.1365-2893.2000.00017.x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25981
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand
Author(s)
Other Contributor(s)
Abstract
A number of studies have suggested that the clinical course of hepatitis A virus (HAV) infection is more severe in patients with chronic liver disease (CLD). A study was undertaken to determine the impact of acute HAV in asymptomatic hepatitis B surface antigen (HBsAg) carriers (n = 20) and patients with hepatitis B virus (HBV)-(n = 8) or hepatitis C virus (HCV)- related (n = 4) CLD. Disease progression was compared with that in 100 patients with isolated HAV infection. No patient with HAV infection alone developed complications, and all recovered fully. Fulminant or submassive hepatitis occurred in 55% of HBsAg carriers and 33% of patients with HBV- or HCV-related CLD. The mortality rate in HBsAg carriers (25%) was not significantly different from that in the patients with CLD (33%). The seroprevalence of anti-HAV immunoglobulin G in 820 individuals was also determined. Approximately 50% of the individuals had acquired HAV infection between the ages of 21 and 30 years. It was demonstrated that HAV infection may have a more severe clinical course in patients with underlying CLD, particularly among older individuals. Vaccination for such patients should be considered.